Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):962-964. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0264

View: 1487 Download: 100 Web of Science: 1 Crossref: 4

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 2465 Download: 161 Web of Science: 6 Crossref: 4

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 2867 Download: 140 Web of Science: 6 Crossref: 7

Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(2):242-251. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0102

View: 6139 Download: 246 Web of Science: 5 Crossref: 6

1 |

Viewed By 6191	MAFLD: How is it different from NAFLD?
Viewed By 5279	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5005	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4169	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 3943	Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Cited By 272	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 225	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 155	MAFLD: How is it different from NAFLD?
Cited By 79	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search